×
NAYA Biosciences EBITDA 2010-2024 | NAYA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
NAYA Biosciences ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
NAYA Biosciences EBITDA 2010-2024 | NAYA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
NAYA Biosciences ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$169.8B
Vertex Pharmaceuticals (VRTX)
$121.4B
Gilead Sciences (GILD)
$109.7B
Bristol Myers Squibb (BMY)
$106.4B
Regeneron Pharmaceuticals (REGN)
$102.2B
CSL (CSLLY)
$92.8B
GSK (GSK)
$79.1B
Alnylam Pharmaceuticals (ALNY)
$36.5B
Argenex SE (ARGX)
$33.1B
BioNTech SE (BNTX)
$27.1B
Biogen (BIIB)
$26.7B
Illumina (ILMN)
$23.3B
Moderna (MRNA)
$21.2B
BeiGene (BGNE)
$21.1B
Genmab (GMAB)
$15.3B
Incyte (INCY)
$14.2B
BioMarin Pharmaceutical (BMRN)
$13.3B
Exact Sciences (EXAS)
$12.9B
Sarepta Therapeutics (SRPT)
$12.4B
Insmed (INSM)
$12.2B
Vaxcyte (PCVX)
$11.8B
Bio-Techne Corp (TECH)
$11.2B
QIAGEN (QGEN)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Revolution Medicines (RVMD)
$8.4B
Legend Biotech (LEGN)
$8.3B
Exelixis (EXEL)
$8.2B
Viking Therapeutics (VKTX)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B